Trevi Therapeutics, Inc. Defined Contribution Plan, Employer Matching Contribution, Percent of Match
Trevi Therapeutics, Inc. (TRVI) reported Defined Contribution Plan, Employer Matching Contribution, Percent of Match of 50.00% for the 1-month period ending 2024-01-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Compensation Related Costs
us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch · last filed 2025-03-18
- 2024-01-31: Defined Contribution Plan, Employer Matching Contribution, Percent of Match 1 month 50.00%.
- 2013-03-31: Defined Contribution Plan, Employer Matching Contribution, Percent of Match 50.00%.
| Period end | Defined Contribution Plan, Employer Matching Contribution, Percent of Match | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 1 month |
|---|---|---|
| 2024-01-31 | 50.00% 10-K · filed 2025-03-18 | |
| 2013-03-31 | 50.00% 10-K · filed 2024-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |